• Explore /
  • Poster
  • / First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study.

First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study.

Abstract Poster

Authors

null

Liangjun Zhu

Jiangsu Cancer Hospital, Nanjing, China;

Liangjun Zhu , Sheng Li , Jun Bao , Xiaoyou Li , Quanliang Yang , Junying Xu , Surong Chen , Ge Feng , Chao Gao , Lin Feng , Bin Lu , Min Miao , Xinchu Ni , Guofang Wang , Lei Yang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

ChiCTR2000029717

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 356)

DOI

10.1200/JCO.2023.41.4_suppl.356

Abstract #

356

Poster Bd #

E17

Abstract Disclosures

Similar Posters

First Author: Patricio Eduardo Yanez

First Author: Zev A. Wainberg

First Author: Deirdre Jill Cohen

First Author: Samuel J Klempner